On the public citation graph
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
0 signed · 346 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archderm.1989.01670190156031openalex-snapshot
Report of the Committee on Infectious Diseases
inferredcites →https://doi.org/10.1001/jama.1986.03370110129041openalex-snapshot
New Vaccine Development: Establishing Priorities, vol 1: Diseases of Importance in the United States
inferredcites →https://doi.org/10.1016/0167-6296(91)90001-4openalex-snapshot
Cost of innovation in the pharmaceutical industry
inferredcites →https://doi.org/10.1016/0264-410x(87)90139-3openalex-snapshot
Vaccine Supply and Innovation
inferredcites →https://doi.org/10.1016/s0095-4543(05)70037-3openalex-snapshot
Vaccination policies and programs
inferredcites →https://doi.org/10.1016/s0264-410x(98)00416-2openalex-snapshot
New technologies for making vaccines
inferredcites →https://doi.org/10.1016/s0264-410x(99)00290-xopenalex-snapshot
The immunization system in the United States — The role of school immunization laws
inferredcites →https://doi.org/10.1016/s0749-3797(01)00274-4openalex-snapshot
National, state, and urban-area vaccination-coverage levels among children aged 19–35 months, United States, 1999
inferredcites →https://doi.org/10.1037/e546382006-001openalex-snapshot
Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP)
inferredcites →https://doi.org/10.1037/e547932006-001openalex-snapshot
Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)
inferredcites →https://doi.org/10.1038/nbt0596-591openalex-snapshot
Vaccine R&D success rates and development times
inferredcites →https://doi.org/10.1086/ipe.1.25056141openalex-snapshot
Creating Markets for New Vaccines. Part I: Rationale
inferredcites →https://doi.org/10.1097/00024382-199910000-00017openalex-snapshot
VACCINES, 3rd Edition
inferredcites →https://doi.org/10.1162/003355304772839588openalex-snapshot
How Much Should We Trust Differences-In-Differences Estimates?
inferredcites →https://doi.org/10.1257/jep.6.3.3openalex-snapshot
Medical Care Costs: How Much Welfare Loss?
inferredcites →https://doi.org/10.1542/peds.102.4.1002openalex-snapshot
United States Vaccine Research: A Delicate Fabric of Public and Private Collaboration
inferredcites →https://doi.org/10.1542/peds.97.6.798openalex-snapshot
Progress Toward Integrating Hepatitis B Vaccine Into Routine Infant Immunization Schedules in the United States, 1991 Through 1994
inferredcites →https://doi.org/10.3386/w6437openalex-snapshot
The Induced Innovation Hypothesis and Energy-Saving Technological Change
inferredcites →https://doi.org/10.3386/w6532openalex-snapshot
Does Government R&D Policy Mainly Benefit Scientists and Engineers?
inferredcites →https://doi.org/10.3386/w6895openalex-snapshot
Your Money and Your Life: The Value of Health and What Affects It
inferredcites →https://doi.org/10.3386/w7716openalex-snapshot
Creating Markets for New Vaccines Part I: Rationale
inferredcites →https://doi.org/10.3386/w9460openalex-snapshot
Health Policy and Technological Change: Evidence from the Vaccine Industry
inferredcites →https://doi.org/10.4159/harvard.9780674432833openalex-snapshot
Invention and Economic Growth
inferredcites →https://doi.org/10.4324/9781003549741-8openalex-snapshot
The Quarterly Journal of Economics
inferredcites →https://doi.org/10.7551/mitpress/3788.001.0001openalex-snapshot
Innovation Policy and the Economy
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.1945419openalex-extracted
Accounting for Anticipation Effects: An Application to Medical Malpractice Tort Reform
inferred← citeshttps://doi.org/10.2139/ssrn.1960609openalex-extracted
The Birth of the Congressional Clinic
inferred← citeshttps://doi.org/10.2139/ssrn.2101246openalex-extracted
The Effect of U.S. Health Insurance Expansions on Medical Innovation
inferred← citeshttps://doi.org/10.2139/ssrn.2109861openalex-extracted
Defensive Investments and the Demand for Air Quality: Evidence from the NOx Budget Program
inferred← citeshttps://doi.org/10.2139/ssrn.2331103openalex-extracted
Implications of Physician Ethics, Billing Norms, and Service Cost Structures for Medicare's Fee Schedule
inferred← citeshttps://doi.org/10.2139/ssrn.2353471openalex-extracted
Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical Trials
inferred← citeshttps://doi.org/10.2139/ssrn.2364595openalex-extracted
When is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity
inferred← citeshttps://doi.org/10.2139/ssrn.2524960openalex-extracted
Of Marshallian Scissors & Blades: Demand Shocks, Import Exposure, and Innovation in Indian Influenza-Vaccine Markets
inferred← citeshttps://doi.org/10.2139/ssrn.2555604openalex-extracted
Why is Pollution from U.S. Manufacturing Declining? The Roles of Trade, Regulation, Productivity, and Preferences
inferred← citeshttps://doi.org/10.2139/ssrn.2573747openalex-extracted
Why is Pollution from U.S. Manufacturing Declining? The Roles of Trade, Regulation, Productivity, and Preferences
inferred← citeshttps://doi.org/10.2139/ssrn.2576481openalex-extracted
Innovation and Uncertainty in the Medical Industry: Evidence from the Case of Myriad Genetics, Inc.
inferred← citeshttps://doi.org/10.2139/ssrn.2646835openalex-extracted
Innovation: The interplay between demand-side shock and supply-side environment
inferred← citeshttps://doi.org/10.2139/ssrn.2724982openalex-extracted
When the Big One Came: A Natural Experiment on Demand Shocks and Market Structure in India’s Influenza Vaccine Markets
inferred← citeshttps://doi.org/10.2139/ssrn.2798876openalex-extracted
Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges
inferred← citeshttps://doi.org/10.2139/ssrn.2805411openalex-extracted
Promoting Innovation in Small Markets: Evidence from the Market for Rare and Intractable Diseases
inferred← citeshttps://doi.org/10.2139/ssrn.2843870openalex-extracted
Why is Pollution from U.S. Manufacturing Declining? The Roles of Trade, Regulation, Productivity, and Preferences
inferred← citeshttps://doi.org/10.2139/ssrn.2933641openalex-extracted
Defensive Investments and the Demand for Air Quality: Evidence from the NOx Budget Program
inferred← citeshttps://doi.org/10.2139/ssrn.3043897openalex-extracted
Endogenous Productivity of Demand-Induced R&D: Evidence from Pharmaceuticals
inferred← citeshttps://doi.org/10.2139/ssrn.3140940openalex-extracted
Combining Life and Health Insurance
inferred← citeshttps://doi.org/10.2139/ssrn.3207503openalex-extracted
When Does Product Liability Risk Chill Innovation? Evidence From Medical Implants
inferred← citeshttps://doi.org/10.2139/ssrn.3251630openalex-extracted
Recalls, Innovation, and Competitor Response: Evidence from Medical Device Firms
inferred← citeshttps://doi.org/10.2139/ssrn.3371223openalex-extracted
Risk-Mitigating Technologies: The Case of Radiation Diagnostic Devices
inferred← citeshttps://doi.org/10.2139/ssrn.3426554openalex-extracted
Global Drug Diffusion and Innovation with a Patent Pool: The Case of HIV Drug Cocktails
inferred← citeshttps://doi.org/10.2139/ssrn.3675020openalex-extracted
Topic Evolution, Disruption and Resilience in Early COVID-19 Research
inferred← citeshttps://doi.org/10.2139/ssrn.3731669openalex-extracted
Regulating Ethical Experimentation: Impacts of the Breakthrough Therapy Designation on Drug R&D
inferred← citeshttps://doi.org/10.2139/ssrn.3830213openalex-extracted
Medicare and the Rise of American Medical Patenting: The Economics of User-Driven Innovation
inferred← citeshttps://doi.org/10.2139/ssrn.3919866openalex-extracted
Anchoring Exploration: Knowledge Certification and the Dynamics of Innovation
inferred← citeshttps://doi.org/10.2139/ssrn.3924439openalex-extracted
Flowers of Invention: Patent Protection and Productivity Growth in US Agriculture
inferred← citeshttps://doi.org/10.2139/ssrn.4015067openalex-extracted
Shall We Fear a Covid-19 Patent Waiver?
inferred← citeshttps://doi.org/10.2139/ssrn.4120273openalex-extracted
Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges
inferred← citeshttps://doi.org/10.2139/ssrn.4142051openalex-extracted
Do Insurance Policies Increase Incentives to Innovate? A Look at Medicare Part D's Effect on Drug Patenting Activity
inferred← citeshttps://doi.org/10.2139/ssrn.4349555openalex-extracted
Distorted Innovation: Does the Market Get the Direction of Technology Right?
inferred← citeshttps://doi.org/10.2139/ssrn.4580204openalex-extracted
Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process
inferred← citeshttps://doi.org/10.2139/ssrn.4612555openalex-extracted
Vaccine Production and Innovation: Insights from Tort Reform and Medicare Expansion
inferred← citeshttps://doi.org/10.2139/ssrn.4676384openalex-extracted
Market Incentives and the Drug Development Pipeline: Evidence from Antibiotics
inferred← citeshttps://doi.org/10.2139/ssrn.4758138openalex-extracted
Product Liability Litigation and Innovation: Evidence from Medical Devices
inferred← citeshttps://doi.org/10.2139/ssrn.5049949openalex-extracted
Automation-Induced Innovation Shift
inferred← citeshttps://doi.org/10.2139/ssrn.625101openalex-extracted
Income Distribution and Demand-Induced Innovations
inferred← citeshttps://doi.org/10.2139/ssrn.982966openalex-extracted
Advance Market Commitments for Vaccines Working Paper and Spread Sheet
inferred← citeshttps://doi.org/10.1002/hec.1176openalex-snapshot
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness
inferred← citeshttps://doi.org/10.1002/hec.4795openalex-snapshot
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required
inferred← citeshttps://doi.org/10.1002/jae.1269openalex-snapshot
MEASURING THE EFFECT OF NAPSTER ON RECORDED MUSIC SALES: DIFFERENCE‐IN‐DIFFERENCES ESTIMATES UNDER COMPOSITIONAL CHANGES
inferred← citeshttps://doi.org/10.1002/mde.1348openalex-snapshot
A primer on the economics of re‐importation of prescription drugs
inferred← citeshttps://doi.org/10.1002/pam.21640openalex-snapshot
Does Targeted, Disease‐Specific Public Research Funding Influence Pharmaceutical Innovation?
inferred← citeshttps://doi.org/10.1002/pam.22586openalex-snapshot
Effect of vaccine recommendations on consumer and firm behavior
inferred← citeshttps://doi.org/10.1007/978-3-031-95735-2_6openalex-snapshot
New Technologies for an Aging Population: Trends and Opportunities
inferred← citeshttps://doi.org/10.1007/s10198-011-0370-7openalex-snapshot
Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan
inferred← citeshttps://doi.org/10.1007/s10198-012-0379-6openalex-snapshot
The impact of health insurance mandates on drug innovation: evidence from the United States
inferred← citeshttps://doi.org/10.1007/s10754-018-9234-3openalex-snapshot
Do coverage mandates affect direct-to-consumer advertising for pharmaceuticals? Evidence from parity laws
inferred← citeshttps://doi.org/10.1007/s11151-018-9621-4openalex-snapshot
Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals
inferred← citeshttps://doi.org/10.1007/s11192-021-03946-7openalex-snapshot
Topic evolution, disruption and resilience in early COVID-19 research
inferred← citeshttps://doi.org/10.1007/s40258-020-00601-9openalex-snapshot
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
inferred← citeshttps://doi.org/10.1007/s41885-022-00106-wopenalex-snapshot
A Literature Review of Pandemics and Development: the Long-Term Perspective
inferred← citeshttps://doi.org/10.1016/b978-0-444-53592-4.00013-xopenalex-snapshot
Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products
inferred← citeshttps://doi.org/10.1016/b978-0-444-53685-3.00008-8openalex-snapshot
Economic Analysis of Risk and Uncertainty Induced by Health Shocks: A Review and Extension
inferred← citeshttps://doi.org/10.1016/bs.hesind.2021.11.013openalex-snapshot
Innovation: market failures and public policies
inferred← citeshttps://doi.org/10.1016/j.chieco.2018.03.003openalex-snapshot
Demand Forces of Technical Change: Evidence From the Chinese Manufacturing Industry
inferred← citeshttps://doi.org/10.1016/j.eap.2026.09.037openalex-snapshot
Tiny salt, grand market: How the reform of the salt monopoly system drives industry innovation
inferred← citeshttps://doi.org/10.1016/j.ijindorg.2022.102840openalex-snapshot
Optimal vaccine subsidies for endemic diseases
inferred← citeshttps://doi.org/10.1016/j.ijindorg.2022.102850openalex-snapshot
Incentives for pharmaceutical innovation: What’s working, what’s lacking
inferred← citeshttps://doi.org/10.1016/j.ijindorg.2025.103157openalex-snapshot
Public procurement as an innovation policy: Where do we stand?
inferred← citeshttps://doi.org/10.1016/j.jdeveco.2020.102578openalex-snapshot
Public health insurance and pharmaceutical innovation: Evidence from China
inferred← citeshttps://doi.org/10.1016/j.jdeveco.2023.103229openalex-snapshot
Health policy, price regulation, and innovation: Evidence from China’s vaccine industry
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2004.08.001openalex-snapshot
Do new prescription drugs pay for themselves?
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2008.01.002openalex-snapshot
Market incentives and pharmaceutical innovation
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2009.06.011openalex-snapshot
R&D policy, agency costs and innovation in personalized medicine
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2011.05.007openalex-snapshot
Opportunities and benefits as determinants of the direction of scientific research
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2011.09.001openalex-snapshot
The other ex ante moral hazard in health
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2017.03.006openalex-snapshot
Promoting innovation in small markets: Evidence from the market for rare and intractable diseases
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2020.102329openalex-snapshot
Insurance access and demand response: Pricing and welfare implications
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2021.102522openalex-snapshot
R&D and market size: Who benefits from orphan drug legislation?
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2021.102549openalex-snapshot
The economics of medical procedure innovation
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2022.102591openalex-snapshot
What drives innovation? Lessons from COVID-19 R&D.
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2022.102671openalex-snapshot
Global drug diffusion and innovation with the medicines patent pool
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2022.102717openalex-snapshot
Health insurance, endogenous medical progress, health expenditure growth, and welfare
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2023.102855openalex-snapshot
Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D
inferred← citeshttps://doi.org/10.1016/j.jjie.2018.01.004openalex-snapshot
South Korea's transition from imitator to innovator: The role of external demand shocks
inferred← citeshttps://doi.org/10.1016/j.jpubeco.2012.10.003openalex-snapshot
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
inferred← citeshttps://doi.org/10.1016/j.jpubeco.2014.10.005openalex-snapshot
Public health insurance expansions and hospital technology adoption
inferred← citeshttps://doi.org/10.1016/j.jpubeco.2015.01.001openalex-snapshot
Interpreting pre-trends as anticipation: Impact on estimated treatment effects from tort reform
inferred← citeshttps://doi.org/10.1016/j.jval.2025.08.011openalex-snapshot
The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs
inferred← citeshttps://doi.org/10.1016/j.mayocp.2018.05.025openalex-snapshot
The Importance of Economic Trade-offs in Cancer Drug Pricing
inferred← citeshttps://doi.org/10.1016/j.qref.2017.07.001openalex-snapshot
Can ‘delitigation’ transform an industry?
inferred← citeshttps://doi.org/10.1016/j.respol.2007.12.009openalex-snapshot
Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act
inferred← citeshttps://doi.org/10.1016/j.respol.2012.04.013openalex-snapshot
Induced innovation and technology trajectory: Evidence from smoking cessation products
inferred← citeshttps://doi.org/10.1016/j.respol.2017.11.011openalex-snapshot
Innovation: The interplay between demand-side shock and supply-side environment
inferred← citeshttps://doi.org/10.1016/j.respol.2020.104126openalex-snapshot
Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling
inferred← citeshttps://doi.org/10.1016/j.respol.2022.104595openalex-snapshot
Generic competition and the incentives for early-stage pharmaceutical innovation
inferred← citeshttps://doi.org/10.1016/j.respol.2022.104633openalex-snapshot
Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak
inferred← citeshttps://doi.org/10.1016/j.respol.2024.105053openalex-snapshot
Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach
inferred← citeshttps://doi.org/10.1016/j.socscimed.2021.114270openalex-snapshot
Macro-level efficiency of health expenditure: Estimates for 15 major economies
inferred← citeshttps://doi.org/10.1016/j.socscimed.2025.117696openalex-snapshot
Health insurance expansion and academic production: The case of Medicare Part D legislation
inferred← citeshttps://doi.org/10.1016/j.ssmph.2019.100440openalex-snapshot
The politics hypothesis and racial disparities in infants’ health in the United States
inferred← citeshttps://doi.org/10.1016/s1574-8715(07)00013-9openalex-snapshot
Chapter 13 Patents and Access to Essential Medicines
inferred← citeshttps://doi.org/10.1017/jme.2026.10294openalex-snapshot
The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine
inferred← citeshttps://doi.org/10.1017/s0022109009990512openalex-snapshot
Pharmaceutical R&D Spending and Threats of Price Regulation
inferred← citeshttps://doi.org/10.1017/s0265052513000083openalex-snapshot
IS IT WRONG TO EAT ANIMALS?
inferred← citeshttps://doi.org/10.1056/nejmsb033394openalex-snapshot
The Fragility of the U.S. Vaccine Supply
inferred← citeshttps://doi.org/10.1073/pnas.2530585123openalex-snapshot
Clinician behavior when skin tone affects test results
inferred← citeshttps://doi.org/10.1080/00036846.2021.1885614openalex-snapshot
Public subsidies for R&D and public sector pharmaceutical innovation
inferred← citeshttps://doi.org/10.1080/10438590902750893openalex-snapshot
How does the management of research impact the disclosure of knowledge? Evidence from scientific publications and patenting behavior
inferred← citeshttps://doi.org/10.1080/10438599.2025.2511865openalex-snapshot
Vaccine production and innovation: insights from tort reform and Medicare expansion
inferred← citeshttps://doi.org/10.1080/13662716.2021.2021864openalex-snapshot
Pharmaceutical spending and early-stage innovation in EU countries
inferred← citeshttps://doi.org/10.1086/595014openalex-snapshot
Input and Technology Choices in Regulated Industries: Evidence from the Health Care Sector
inferred← citeshttps://doi.org/10.1086/605851openalex-snapshot
Incentivizing Innovation: Adding to the Tool Kit
inferred← citeshttps://doi.org/10.1086/648383openalex-snapshot
Altruism and Innovation in Health Care
inferred← citeshttps://doi.org/10.1086/684986openalex-snapshot
Intellectual Property Rights and Innovation: Evidence from Health Care Markets
inferred← citeshttps://doi.org/10.1086/689772openalex-snapshot
In the Shadow of a Giant: Medicare’s Influence on Private Physician Payments
inferred← citeshttps://doi.org/10.1086/693038openalex-snapshot
Asymmetric Growth and Institutions in an Interdependent World
inferred← citeshttps://doi.org/10.1086/699934openalex-snapshot
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
inferred← citeshttps://doi.org/10.1086/702923openalex-snapshot
Labor Markets in Statistics: The Subject Supply Effect in Medical R&D
inferred← citeshttps://doi.org/10.1086/705640openalex-snapshot
The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals
inferred← citeshttps://doi.org/10.1086/708094openalex-snapshot
Still in Mortal Peril? Recent Research Suggests a New Agenda for Health Care Reform
inferred← citeshttps://doi.org/10.1086/708706openalex-snapshot
Financial Reporting Frequency and Corporate Innovation
inferred← citeshttps://doi.org/10.1086/713497openalex-snapshot
How Would Medicare for All Affect Health System Capacity? Evidence from Medicare for Some
inferred← citeshttps://doi.org/10.1086/734328openalex-snapshot
Health-Care Spending Growth Has Slowed
inferred← citeshttps://doi.org/10.1086/741278openalex-snapshot
DYNAMIC EFFICIENCY AND PRICING OF PHARMACEUTICAL INNOVATIONS
inferred← citeshttps://doi.org/10.1093/0195305191.003.0021openalex-snapshot
Public Policies to Stimulate Development of Vaccines for Neglected Diseases
inferred← citeshttps://doi.org/10.1093/acprof:oso/9780199550685.003.0005openalex-snapshot
Insurance and new technology
inferred← citeshttps://doi.org/10.1093/ej/ueab091openalex-snapshot
Spillover Effects of Intellectual Property Protection in the Interwar Aircraft Industry
inferred← citeshttps://doi.org/10.1093/haschl/qxae129openalex-snapshot
Evidence to inform biopharmaceutical policy: call for research on the impact of public policies on investment in drug development
inferred← citeshttps://doi.org/10.1093/haschl/qxaf200openalex-snapshot
Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?
inferred← citeshttps://doi.org/10.1093/haschl/qxag160openalex-snapshot
The effect of market size on pharmaceutical innovation: matching estimates to policy questions
inferred← citeshttps://doi.org/10.1093/icc/dtab064openalex-snapshot
The long-term economic effects of pandemics: toward an evolutionary approach
inferred← citeshttps://doi.org/10.1093/oso/9780190946838.001.0001openalex-snapshot
The Ethics of Universal Health Insurance
inferred← citeshttps://doi.org/10.1093/oso/9780190946838.003.0002openalex-snapshot
Information about Health Care Systems
inferred← citeshttps://doi.org/10.1093/oso/9780190946838.003.0003openalex-snapshot
The Ethical Issues Raised in Health Care Debates
inferred← citeshttps://doi.org/10.1093/oso/9780190946838.003.0007openalex-snapshot
The Case for Universal Health Insurance
inferred← citeshttps://doi.org/10.1093/oso/9780190946838.003.0008openalex-snapshot
Beyond Health Care
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.001.0001openalex-snapshot
Why Not Better and Cheaper?
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0001openalex-snapshot
Introduction and Overview
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0002openalex-snapshot
Economically Valuable Innovation
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0003openalex-snapshot
Missing Innovations
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0005openalex-snapshot
Beyond Financial Incentives
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0006openalex-snapshot
Competition, Innovation, and Disruption
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.003.0007openalex-snapshot
Dilemmas and Opportunities
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.005.0001openalex-snapshot
Does Innovation Respond to Expected Profits?
inferred← citeshttps://doi.org/10.1093/oso/9780197603109.005.0002openalex-snapshot
Are Innovations Overlooked in Other Sectors?
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0001openalex-snapshot
Why We Need Cost-Effectiveness Analysis, How It Is Done, and Why It Needs Fixing
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0002openalex-snapshot
Diminishing Returns . . . Everywhere
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0003openalex-snapshot
How Uncertain Treatment Outcomes Affect Value
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0004openalex-snapshot
The Total Value of Medical Interventions and the Trade-Off Between Quality of Life and Life Expectancy
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0005openalex-snapshot
The Consequences of Permanent Disability
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0006openalex-snapshot
Multiperiod Models
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0007openalex-snapshot
In Search of Decision Thresholds
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0008openalex-snapshot
Measuring the Risk Parameters
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0009openalex-snapshot
Putting Together the Parts
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0011openalex-snapshot
Consequences for Health Plans
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0012openalex-snapshot
Welfare and Equity Implications of GRACE
inferred← citeshttps://doi.org/10.1093/oso/9780197686287.003.0013openalex-snapshot
Conclusions and Next Steps
inferred← citeshttps://doi.org/10.1093/oxfordhb/9780199742998.013.0006openalex-snapshot
Incentives to Innovate
inferred← citeshttps://doi.org/10.1093/oxfordhb/9780199742998.013.0017openalex-snapshot
The Economics of Vaccines
inferred← citeshttps://doi.org/10.1093/qje/121.1.1openalex-snapshot
The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing
inferred← citeshttps://doi.org/10.1093/qje/qjad036openalex-snapshot
Representation and Extrapolation: Evidence from Clinical Trials
inferred← citeshttps://doi.org/10.1093/qje/qju029openalex-snapshot
Patents and Cumulative Innovation: Causal Evidence from the Courts *
inferred← citeshttps://doi.org/10.1093/qje/qjz037openalex-snapshot
Combining Life and Health Insurance*
showing the first 200 of 319 · page through all 319
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.